| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2022: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2021: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2020: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2019: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2018: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Outline of Final Research Achievements |
Activation of the innate immune system, which occurs not only during cell and organ transplantation but also during artificial organs implantation such as artificial hearts and artificial dialysis, is a important issue that has yet to be resolved. We aimed to fabricate materials which can modify the surface, that can protect against attacks by the innate immune response during transplantation. Here we selected heparin as a regulator of the complement and coagulation systems, and succeeded in conjugating it to polyethylene glycol (PEG)-conjugated lipids. As an alternative material, we also succeeded in synthesis of a lipid conjugate using 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer. Both materials are expected to function to protect the surface from the innate immunity activation.
|
